Francisco Ujueta/LinkedIn;
Eric A Secemsky/LinkedIn
Apr 12, 2026, 13:44
Francisco Ujueta: PAD VS CAD – Why Individualized Antithrombotic Strategies Matter
Francisco Ujueta, Vascular Cardiologist at Vanderbilt University Medical Center, shared a post on LinkedIn about a recent article he and his colleague co-authored, adding:
“View our commentary on differences in PAD and CAD – emphasizing higher ischemic and bleeding risks, greater heterogeneity, and the need for individualized antithrombotic strategies.”
Title: Too much, too little, or just right: Tailoring postrevascularization antithrombotic therapy in PAD versus CAD when one size does not fit all
Authors: Francisco Ujueta, Eric A Secemsky
Read the Full Article on Vascular Medicine
Stay updated with Hemostasis Today.
-
May 6, 2026, 10:55Hugo Antonio Romo Rubio: A New Paradigm in Treatment for Hemophilia A from FRONTIERS2 Phase 3 Study
-
May 6, 2026, 10:40Ifeanyichukwu Ifechidere: Why INR Can Be Dangerously Misleading
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?
-
May 6, 2026, 02:47Karen Rollinson: Connecting with so Many Families and Advocates at HFA 2026
-
May 6, 2026, 02:38Moustafa Abdou: Is the Bone Marrow Examination Still the ‘Gold Standard’?
-
May 6, 2026, 02:23Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
-
May 6, 2026, 02:12Caitlin Raymond: How STOP-BABESIOSIS Just Rewrote 40 Years of Practice
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention
-
May 5, 2026, 16:23Satyam Arora: Best Abstract Award in Pediatric Apheresis at ASFA 2026 Congress